TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›HLI
HLI logo

HLI

HOULIHAN LOKEY, INC.

Next earnings Jul 27, 2026 · consensus $1.85 EPS, $645M rev

Last earnings +4.3% on 2026-05-07

Buy
$140.15
▲ +5.44%
$140.15▼ -22.06%
over 1Y
L $132.92H $206.68
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.4%
1W+2.8%
1M+0.5%
3M-0.3%
YTD-19.8%
1Y-22.1%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Buy
Quality
B-
Valuation
Fair value
Filings
Watch
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 14 analysts
Hold

Premier independent advisory bank with a counter-cyclical restructuring hedge, 18% ROE and record revenue, at a deserved 23x.

Revenue $2.62B · FY2026

The read

Solid fundamentals at a roughly fair price — reasonable risk/reward at today's level.

Houlihan Lokey is the highest-quality independent investment bank in the public market, and its FY2026 results extend a record of resilient growth. Revenue rose 9.5% to $2.62B (a fresh high), operating income grew 4.9% to $527M, net income rose 6.5% to $426M, and diluted EPS climbed 6.9% to $6.22. The firm earns a 20.1% operating margin and 18.2% ROE — strong for an advisory business — and the recovery from the FY2023 deal-drought trough ($254M net income) back to records shows the model's durability. Crucially, HLI's revenue is diversified across Corporate Finance (M&A), Financial Restructuring, and Financial & Valuation Advisory, and the 10-K spells out the natural hedge: weak markets hurt M&A but boost the restructuring (FR) business, while strong markets do the reverse — smoothing earnings across the cycle.

The balance sheet is a fortress for a capital-light advisory firm: $1.19B cash (+22.5%), minimal debt, liabilities/equity of only 0.79x, and retained earnings up 18.0% to $1.65B. The business needs almost no capital ($22.3M capex) and converts profit to cash, funding generous capital return — buybacks more than tripled to $175M and the dividend grew 5.3% to $174M. The slight dip in operating cash flow (-17.0% to $704M) reflects working-capital timing on deal fees, not a deterioration in earnings.

Is HLI a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bull call spread (wide)~90d expiry
  • Long call 140 @ ~10.04 est
  • Short call 161 @ ~3.12 est
debit $692max +$1,408max −$692BE 146.92

High-conviction BUY: a wider spread keeps more of the upside while the short call still cuts cost and decay.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY22FY23FY24FY25FY26
Revenue$2.27B$1.81B$1.91B$2.39B$2.62B
Gross profit$795M$557M$571M$772M—
Operating income$613M$342M$373M$503M$527M
Net income$438M$254M$280M$400M$426M
Diluted EPS$6.41$3.76$4.11$5.82$6.22
Net margin19.3%14.0%14.6%16.7%16.3%

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF14.2
PEG (trailing)3.47
Earnings yield4.4%
FCF yield7.0%

Quality & risk

ROIC (est.)17.4%
Free cash flow$682M
Total debt$55.9M
Net cash$1.13B
Piotroski F-Score4/8

Capital returns

Buyback yield1.8%
Dividend yield (est.)1.8%
Shareholder yield3.6%
Shares Δ YoY+1.3%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 10-K Annual report2026-05-22
  2. 8-K Earnings results2026-05-07
  3. 8-K Other event2026-02-25
  4. 10-Q Quarterly report2026-02-03
  5. 8-K Officer / director change2026-01-29
  6. 8-K Earnings results2026-01-29
  7. 8-K Material agreement2025-12-30
  8. 10-Q Quarterly report2025-11-04
  9. 8-K Earnings results2025-10-31

Recent filings

all on EDGAR ↗
10-KPeriod ending 2026-03-312026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-21open ↗4Period ending 2026-05-212026-05-21open ↗4Period ending 2026-05-212026-05-21open ↗4Period ending 2026-05-212026-05-21open ↗4Period ending 2026-05-212026-05-21open ↗4Period ending 2026-05-212026-05-21open ↗4Period ending 2026-05-212026-05-21open ↗

Quality score

B-
ValueGrowthProfitHealthMom.
ValueB-
GrowthB
ProfitabilityA
Financial healthA-
MomentumF
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✓Net margin above 10%
  • ✓Return on equity above 15%
  • ✓P/E below 25

Fair value est.

$140.50

Fairly valued +0% vs price

cheapfair valueexpensive

Modified Graham: EPS $6.22 × (8.5 + 1.5 × 8.0% growth) × 1.10 quality = 22.6× multiple. An estimate, not a price target.

132.9252-week206.68
Revenue
$2.62B
+9.5% YoY
Net margin
16.3%
ROE
18.2%
P/E
22.5

SEC fundamentals · FY 2026

'22'23'24'25'26

■ revenue · ■ net income, by fiscal year

Revenue$2.62B+9.5%
Net income$426M+6.5%
Gross profit$772M+35.2%
Operating income$527M+4.9%
Diluted EPS$6.22+6.9%
Cash & equivalents$1.19B+22.5%
Total assets$4.31B+12.8%
Total liabilities$1.86B+12.8%
Stockholders' equity$2.34B+7.7%
Gross: 29.5%Op.: 20.1%L/E: 0.79x

Frequently asked

Is HOULIHAN LOKEY, INC. (HLI) a buy?
HLI currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Premier independent advisory bank with a counter-cyclical restructuring hedge, 18% ROE and record revenue, at a deserved 23x.
What is HLI's fair value?
A Modified-Graham model based on HLI's SEC fundamentals estimates a fair value of about $140.50. It is an estimate from reported earnings, not a price target.
Is HLI overvalued or undervalued?
Against a Modified-Graham fair-value estimate, HLI currently appears fairly valued relative to its SEC-grounded earnings power.
What is HOULIHAN LOKEY, INC.'s quality score?
HLI scores 69.64506486947018/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001302215, latest 10-K filed 2026-05-22) · EODHD · Proprietary analysis · as of 6/21/2026, 8:50:26 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:50 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 1 sale

2026-05-21
BEISER SCOTT L
CO-CHAIRMAN
Acquired (C)6.26K
2026-05-21
BEISER SCOTT L
CO-CHAIRMAN
Sell6.26K @ $150.26$941K
2026-05-21
Walker Cyrus D.
Director
Award996.00
2026-05-21
Bassey Ekpedeme M
Director
Award797.00
2026-05-21
Zucker Gillian Beth
Director
Award996.00

Dividends

Quarterly
Yield (TTM)
1.8%
Annual / share
$2.50
Last ex-date
2026-06-01
Last amount
$0.70
ex 2026-06-01paid 2026-06-15$0.70
ex 2026-03-02paid 2026-03-15$0.60
ex 2025-12-01paid 2025-12-15$0.60
ex 2025-09-02paid 2025-09-15$0.60
ex 2025-06-02paid 2025-06-15$0.60
ex 2025-03-03paid 2025-03-15$0.57

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-05-07Miss -11.7% est▼ -1.06%8-K ↗
2026-01-29Beat +2.9% est▼ -12.11%8-K ↗
2025-10-31Beat +7.0% est▼ -10.03%8-K ↗
2025-07-30Beat +26.3% est▼ -3.40%8-K ↗
2025-05-08—▲ +8.26%8-K ↗
2025-01-29—▼ -3.44%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Congressional trades

all activity →

1 buy · 1 member · last 180d

+$8.00K net boughtlast trade 124d ago
$8.00K bought$0.00 sold
2026-04-07Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2025-06-18Kelly Louise MorrisonSell$1.00K–$15.0KPTR ↗
2025-05-14Josh GottheimerSell$1.00K–$15.0KPTR ↗
2024-01-07Josh GottheimerSell$1.00K–$15.0KPTR ↗
2023-02-17Josh GottheimerSell$1.00K–$15.0KPTR ↗
2019-11-15Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2019-10-16Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2019-10-11Josh GottheimerBuy$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Vs tracked universe

compare →

1194 tracked peers · median

TENK Score70 vs 67
Revenue growth9.5% vs 7.5%
Net margin16.3% vs 10.0%
Return on equity18.2% vs 12.0%
P/E22.5 vs 26.2